CLASSIFICATION AND ETIOLOGY
IE can be divided into three categories: native valve endocarditis, prosthetic valve endocarditis (PVE) and endocarditis in IDUs. Native valve IE is most commonly caused by Streptococcus species, Staphylococcus aureus and Enterococcus species (5) . Most patients (60% to 80%) with IE have an identifiable, predisposing cardiac lesion such as a bicuspid aortic valve, a mitral valve prolapse or rheumatic valvular disease (6, 7) . Endocarditis can also be classified as acute or subacute. Acute IE is caused by virulent organisms such as S aureus, which can infect normal heart valves and are rapidly fatal if not treated promptly. Subacute IE results from infection of structurally abnormal valves by less virulent organisms such as viridans streptococci.
PVE can be further subclassified as early or late. Early infection occurs within two months of valve replacement and is usually due to contamination during surgery. Staphylococcus epidermidis and S aureus are the most common organisms identified in this situation (8, 9) . Late PVE occurs more than two months after valve replacement, and is usually due to transient bacteremia with subsequent seeding of the valve, although some cases may still result from organisms acquired during the surgery. Streptococci are the most commonly isolated organisms in late PVE, followed by staphylococci and, much less commonly, Gram-negative rods and fungi (9) (10) (11) .
Infective endocarditis in IDUs usually involves the tricuspid valve, although left-sided endocarditis may also occur in IDUs with pre-existing valve abnormalities. S aureus is the most common organism isolated, followed by enterococci, streptococci and Gram-negative rods such as Pseudomonas species and Serratia species (12) .
CLINICAL MANIFESTATIONS
Most patients with IE present with fever along with nonspecific symptoms such as chills, night sweats, anorexia and fatigue (11, 13) . The fever is usually low grade and remittent in cases of subacute IE, with temperatures rarely exceeding 39°C; however, temperatures may be higher in cases associated with virulent organisms such as S aureus (14) . Musculoskeletal complaints are present in approximately 40% of patients, with arthralgias, myalgias and back pain being the most common. Most patients (90%) with IE have a murmur, although a new or changing murmur is only observed in 36% to 53% (13) . Cutaneous manifestations such as petechiae and splinter hemorrhages may be observed in up to 50% of patients. Splenomegaly is now a relatively uncommon finding, being observed in less than 20% of patients (1, 6) .
Many patients may initially present with a complication of IE. Congestive heart failure is the most common complication and is observed in 38% to 60% of IE patients (14) . Embolic phenomena are the second most frequent complication and may occur at any time during the course of the illness (15) . Occasionally, the patient may present with an acute cerebrovascular accident. Patients with right-sided IE may present with multiple, rounded pulmonary infiltrates with or without cavitation due to infected pulmonary emboli (1) . Mycotic aneurysms are the third most common complication, occurring in 5% to 10% of cases. These often involve the central nervous system and may be clinically silent until they rupture (16) . Other complications include the development of renal dysfunction due to embolization of the kidneys or the development of immune-mediated glomerulonephritis (1).
LABORATORY FINDINGS
Common laboratory findings in IE include normochromic normocytic anemia (70% to 90% of cases), leukocytosis (20% to 30%), an elevated erythrocyte sedimentation rate (greater than 90%), elevated C-reactive protein levels, positive rheumatoid factor (40% to 50%), proteinuria (50% to 65%) and hematuria (30% to 50%) (17) . Most patients with IE (78% to 95%) have a positive blood culture. Prior antibiotic therapy is the most common reason for negative blood cultures in a patient with IE (5).
DIAGNOSIS
An early diagnosis requires a high degree of clinical suspicion, because patients with IE may present with nonspecific symptoms. Blood cultures should be obtained from all individuals suspected of having IE, and all should undergo echocardiography. Transesophageal echocardiography can detect both vegetations and perivalvular infections with a sensitivity of 80% to 90%, and is superior to transthoracic echocardiography for diagnosing IE (18, 19) . Serial blood cultures should be obtained if the original blood culture is negative. Once an organism has been isolated and identified, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration should be determined to guide further antimicrobial therapy.
The Duke's criteria (19) use clinical, microbiological and echocardiographic findings to establish a diagnosis of definite or possible IE, and have largely supplanted previously described criteria for IE (20) . Two major, or one major plus three minor, or five minor criteria establish a definitive clinical diagnosis of IE (Table 1) .
THERAPY OF IE
Ideally, all patients with a suspected diagnosis of IE should be admitted for diagnostic workup and monitoring. Empirical therapy with a bactericidal antibiotic regimen should be initiated in all patients with acute IE while awaiting the culture results. An early surgical consultation should be obtained in any patient developing a complication of IE and in all patients with PVE (14) . Indications for surgical therapy for IE are outlined in Table 2, while Tables 3 to 5 summarize the empirical antibiotic regimens for the different types of IE. Therapy for subacute endocarditis can usually be delayed for 24 to 48 h, until the culture results become available. Definitive therapy is based on the culture results, and is outlined in Tables 3 to 6 .
DEFINITIVE THERAPY OF IE
The recommended treatment regimens for native valve, prosthetic valve and right-sided IE are listed in Tables 3, 4 and 5, respectively. Table 6 outlines the treatment choices available for managing IE in penicillin-allergic patients. Native valve endocarditis -Viridans streptococci: Specific therapy of streptococcal infections is based on their suscepti-bility to penicillin G (21) . Those with MICs of 0.1 mg/mL or less can be managed with a four-week course of penicillin or ceftriaxone, or a two-week course of penicillin or ceftriaxone plus gentamicin (21) (22) (23) . A two-week course of ceftriaxone followed by two weeks of oral amoxicillin has also been shown to be effective (23) . Streptococci with penicillin G MICs between 0.1 and 0.5 mg/mL require a regimen of high dose penicillin G for four weeks, plus gentamicin for the first two weeks (21) . This regimen can also be used for nutrient-deficient streptococci. Penicillin may not be bactericidal against streptococci with penicillin G MICs greater than 0.5 mg/mL. These organisms should be treated with the same regimens as enterococci (21) .
Vancomycin can be substituted for penicillin in patients with a history of penicillin allergy. Ceftriaxone is also an alternative in this situation because of the minimal cross-reactivity between penicillin and third-generation cephalosporins. Enterococci: Penicillin, ampicillin and vancomycin are not bactericidal against enterococci, and the addition of an aminoglycoside such as streptomycin or gentamicin is required to produce a synergistic bactericidal effect. Synergy is only seen if the MIC is less than 2000 mg/mL or less than 500 mg/mL to streptomycin and gentamicin, respectively (21) . The usual treatment course is for six weeks. No satisfactory regimens are available to treat enterococci that have high level resistance to aminoglycosides. Staphylococci: A four-to six-week course of intravenous cloxacillin remains the treatment of choice for methicillinsusceptible S aureus and S epidermidis (21) . Cefazolin may be substituted for cloxacillin in selected patients with a penicillin allergy (21) . The addition of gentamicin for the first three to five days of therapy produces a more rapid clearing of the bacteremia but has not been shown to reduce the complication rate or increase the cure rates (24) . Current evidence suggests that vancomycin may be less effective than cloxacillin in treating IE and s-
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may also produce late PVE. A combination of intravenous vancomycin, gentamicin and oral rifampicin is a good empirical regimen for PVE (21) . Specific regimens are given in Table 4 . All treatment courses are for six weeks unless otherwise indicated. Early surgical consultation should be obtained in all cases of PVE (14) .
Endocarditis in IDUs:
Staphylococcus aureus is the most common etiological organism in this situation. A two-week regimen of cloxacillin plus gentamicin is curative in most cases of uncomplicated infection, especially if a clinical and bacteriological response is seen within 96 h of initiating therapy (27) . A longer treatment course should be given if there is evidence of complications such as hemodynamic compromise, systemic emboli or a metastatic focus of infection. A four-week oral regimen of ciprofloxacin plus rifampicin is also effective, although this regimen should not be used for treating methicillin-resistant S aureus infections (28).
OPAT FOR IE
OPAT for IE is an increasingly attractive option in the current climate of cost containment. The availability of single, daily dose regimens and computerized ambulatory infusion pumps has made it possible to provide optimal home intravenous therapy for most cases of IE while minimizing the need for a prolonged hospital admission. The approach to placing a patient on home intravenous therapy is outlined in Figure 1 .
The choice of the antibiotic regimen for OPAT will depend on the type of infecting organism, the method of administration (ie, with or without a programmable infusion pump) and the ability of the patient to self-administer the antibiotics. Penicillinand cloxacillin-based regimens are the most economical if the patient is able to self-administer the drugs or if it is possible to use an infusion pump. If a nursing visit is required to administer each dose, then the use of more expensive once-a-day agents such as ceftriaxone becomes more economical.
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Can Patients selected for home intravenous therapy must be medically stable and should be monitored in hospital for at least the first week of intravenous therapy. They should also meet the general eligibility criteria for home intravenous therapy. The patients and their caregivers should be familiar with the risk of embolic complications and informed that the risk of complications is the same with both inpatient and outpatient therapy. The patients should be instructed to report immediately any new symptoms that develop and should have prompt access to medical care in the event of complications.
The patient should report any new fever, systemic symptoms (eg, night sweats, malaise, weakness) or embolic complications that develop during therapy. All patients should have complete blood counts and renal function tests (urea and creatinine) performed weekly. Patients being managed with aminoglycosides should have the peak antibiotic level measured at the start of therapy, followed by weekly measurements of trough levels to minimize the risk of toxicity. The desired peak and trough levels for gentamicin are 3 to 4 mg/L and less than 1.0 mg/L, respectively. Patients on oral rifampin should also have weekly measurements of the transaminases (aspartase aminotransferase, alanine aminotransferase) and alkaline phosphatase.
There have been no prospective, controlled trials to determine whether inpatient therapy and OPAT are equivalent in terms of mortality and morbidity. Three small studies with a cumulative total of 100 patients with streptococcal IE suggest that home intravenous therapy is safe and efficacious for this indication (22, 23, 29) . Only two patients relapsed while on therapy in these reports. A fourth retrospective study reported that only four of seven patients (56%) completed the antibiotic course because of the development of complications (30) . None of these patients relapsed, but three patients did report intravenous-related complications.
In conclusion, most cases of IE can be managed safely, economically and effectively with OPAT. Most of the recommended treatment regimens can be delivered as effectively at home as in the hospital. While there are no prospective, controlled trials to document the benefits of this approach, the authors' own personal experience and the evidence from several published reports suggests that home intravenous therapy is safe and effective.
